Finasteride Tablets

This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5alpha;-reductase competitive inhibitor, inhibiting the conversion of peripheral testosterone into dihydrotestosterone, and reducing the level of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

The main ingredient of this product is finasteride, its chemical name: 17beta;-(N-tert-butylcarbamoyl)-4-aza-5alpha;-androst-1-ene-3-one

This product is a film-coated tablet, which appears white or off-white after removing the film coating.

This product is suitable for the treatment of symptomatic benign prostatic hyperplasia (BPH). It improves symptoms; reduces the risk of acute urinary retention; and reduces the risk of transurethral resection of the prostate (TURP) and prostatectomy.

Oral. Recommended dose: 5 mg (1 tablet) once a day, either on an empty stomach or with food.

Finasteride has good tolerance, and most adverse reactions are mild and short-lived. Literature reports: 1 Adverse reactions with an incidence rate of ge;1% are mainly sexual dysfunction (impotence, decreased libido, ejaculation disorder), breast discomfort (breast enlargement, breast pain) and rash. The incidence of adverse events after one year of use of this product is as follows (the brackets are the placebo control group), and the cumulative incidence after two to four years of use of the product shows a downward trend. Impotence: 8.1% (3.7%). Decreased libido: 6.4% (3.4%). Decreased semen volume: 3.7% (0.8%). Ejaculation disorder: 0.8% (0.1%). Breast enlargement: 0.5% (0.1%). Breast pain: 0.4% (0.1%). Rash: 0.5%. 2 Reports after the product is marketed

This product is not suitable for women and children. This product is contraindicated in the following situations: 1. People who are allergic to any ingredient of this product. 2. Pregnant women or women who may become pregnant.

Precautions for children: Forbidden to use in children Precautions for pregnancy and lactation: Forbidden to use in women Precautions for the elderly: No dosage adjustment is required for elderly patients.

No clinically significant drug interactions have been identified. 1 Finasteride has no significant effect on the cytochrome P450-related drug metabolizing enzyme system. Compounds that have been tested in men include propranolol, digoxin, glibenclamide, warfarin, theophylline, and antipyrine, none of which have been found to have clinically significant interactions with finasteride. 2 Other combined therapies. Although no specific drug interaction studies have been conducted, in clinical studies, no significant clinical adverse interactions were found when finasteride was used simultaneously with angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, alpha-blockers, beta-blockers, calcium channel blockers, nitrates for heart disease, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones, and benzodiazepines.

Keep tightly closed in a cool place.

5mg

24 months

Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd.

• Founded in:

  2001-08-17

• Address:

  No. 802, South Section of Rainbow Avenue, Dujiangyan City, Chengdu City, Sichuan Province

• Tax NO.:

  91510181730231740X

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view